WO2019112269A1 - Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 - Google Patents
Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 Download PDFInfo
- Publication number
- WO2019112269A1 WO2019112269A1 PCT/KR2018/015184 KR2018015184W WO2019112269A1 WO 2019112269 A1 WO2019112269 A1 WO 2019112269A1 KR 2018015184 W KR2018015184 W KR 2018015184W WO 2019112269 A1 WO2019112269 A1 WO 2019112269A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chloro
- pyrimidin
- amine
- pyrrolo
- pyrazol
- Prior art date
Links
- 0 CC(C)(C)OC(N1CCC(*)CC1)=O Chemical compound CC(C)(C)OC(N1CCC(*)CC1)=O 0.000 description 3
- OUZMXGKGLFQIBO-UHFFFAOYSA-N CC(C)[n](cc1N)nc1OC Chemical compound CC(C)[n](cc1N)nc1OC OUZMXGKGLFQIBO-UHFFFAOYSA-N 0.000 description 1
- KVGUTQXKALMKGB-UHFFFAOYSA-N COCC[n](cc1N)nc1Cl Chemical compound COCC[n](cc1N)nc1Cl KVGUTQXKALMKGB-UHFFFAOYSA-N 0.000 description 1
- QAXVQYCZCDFSIB-UHFFFAOYSA-N CSc1ncc2c(Cl)n[n](C3CC3)c2n1 Chemical compound CSc1ncc2c(Cl)n[n](C3CC3)c2n1 QAXVQYCZCDFSIB-UHFFFAOYSA-N 0.000 description 1
- AGWLXOOSYMVWMI-UHFFFAOYSA-N Nc(cn[n]1C(C2)CN2C2COC2)c1Cl Chemical compound Nc(cn[n]1C(C2)CN2C2COC2)c1Cl AGWLXOOSYMVWMI-UHFFFAOYSA-N 0.000 description 1
- BQIWENHODWSHGD-UHFFFAOYSA-N Nc1c[n](C(CC2)CCN2C(N2CCOCC2)=O)nc1Cl Chemical compound Nc1c[n](C(CC2)CCN2C(N2CCOCC2)=O)nc1Cl BQIWENHODWSHGD-UHFFFAOYSA-N 0.000 description 1
- FFTRSILXQBIOTB-UHFFFAOYSA-N [O-][N+](c1c[nH]nc1C(F)(F)F)=O Chemical compound [O-][N+](c1c[nH]nc1C(F)(F)F)=O FFTRSILXQBIOTB-UHFFFAOYSA-N 0.000 description 1
- JSTHZKWDZSLMQO-UHFFFAOYSA-N [O-][N+](c1c[n](C2CNCC2)nc1)=O Chemical compound [O-][N+](c1c[n](C2CNCC2)nc1)=O JSTHZKWDZSLMQO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to pyrrolo (pyrazolo) pyrimidine derivatives having an effect as an inhibitor of LRRK2 (Leucine-rich repeat kinase 2) and pharmaceutical compositions for preventing or treating degenerative brain diseases comprising the same.
- LRRK2 Leucine-rich repeat kinase 2
- LRRK2 Leucine-rich repeat kinase 2
- GTPase GTPase
- serine-threonine kinase activity in one protein.
- LRRK2 is reported to be highly expressed in dopaminergic neurons in the cerebral cortex, black body, striatum, hippocampus, cerebellum, etc., which are associated with the pathogenesis of Parkinson's disease.
- specific expression of LRRK2 was observed in abnormal protein aggregates called Lewy bodies, which are observed as specific diseases in dopaminergic neurons in patients with Parkinson's disease.
- LRRK2 gain-of-function'mutant of LRRK2 is closely related to the onset of late-onset autosomal dominant Parkinson's disease, and LRRK2 Increased activity is known to affect onset and progression of Parkinson's disease.
- LRRK2 when normal LRRK2 is overexpressed in neurons, apoptosis is induced.
- This LRRK2-induced cell physiological change pattern is very similar to the neuronal cell death in Parkinson's disease patients .
- the activation of LRRK2 has a high clinical relevance to the onset and progression of Parkinson's disease, and it is possible to control both the neuronal apoptosis and neuronal inflammatory response, which are the most important pathological changes of Parkinson's disease, through the regulation of LRRK2 activity It is expected.
- the present inventors have made efforts to develop a compound which exhibits selective and excellent activity in LRRK2.
- a novel pyrrolo (pyrazolo) pyrimidine derivative was synthesized and showed that the derivative exhibits excellent LRRK2 activity inhibitory effect. Completed.
- an object of the present invention is to provide a novel compound having an excellent LRRK2 activity inhibitory effect.
- An aspect of the present invention provides a compound selected from the group consisting of a compound represented by the following formula (1), and a pharmaceutically acceptable salt, hydrate, solvate, prodrug, and isomer thereof:
- X is CH or N
- R 1 is hydrogen, halogen, or C 1-4 alkyl or C 1-4 alkoxy unsubstituted or substituted with one or more halogens;
- R 2 is C 1-6 alkyl, C 1-3 alkoxy C 1-6 alkyl, C 3-6 cycloalkyl C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, 4-7 membered Heterocycloalkyl, or C 6-10 aryl optionally substituted with one or more halogens;
- heterocycloalkyl of 4 to 7 circle C 1-4 alkyl, optionally substituted with one or more halogen C 1-4 alkylcarbonyl, C 3-6 cycloalkyl-carbonyl, C 1-4 alkyl substituted with Unsubstituted 4 to 7 membered heterocycloalkylcarbonyl, C 1-4 alkylsulfonyl, C 3-6 cycloalkylsulfonyl, or oxetanyl,
- heterocycloalkyl comprises at least one atom selected from N, O and S,
- R 3 is hydrogen, halogen, or C 1-4 alkyl
- R 4 is C 1-6 alkyl or C 3-6 cycloalkyl optionally substituted with one or more halogens;
- R < 5 > is halogen, or C1-4 alkyl optionally substituted with one or more halogens.
- Another aspect of the present invention provides a pharmaceutical composition for preventing or treating a degenerative brain disease comprising the compound as an active ingredient.
- the pyrrolo (pyrazolo) pyrimidine derivative according to the present invention has an excellent selective inhibitory effect on LRRK2 and is useful as a preventive and therapeutic agent for degenerative brain diseases including Parkinson's disease.
- halogen examples include fluorine, chlorine, bromine and iodine.
- X is CH or N
- R 1 is hydrogen, halogen, or C 1-4 alkyl or C 1-4 alkoxy unsubstituted or substituted with one or more halogens;
- R 2 is C 1-6 alkyl, C 1-3 alkoxy C 1-6 alkyl, C 3-6 cycloalkyl C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, 4-7 membered Heterocycloalkyl, or C 6-10 aryl optionally substituted with one or more halogens;
- heterocycloalkyl of 4 to 7 circle C 1-4 alkyl, optionally substituted with one or more halogen C 1-4 alkylcarbonyl, C 3-6 cycloalkyl-carbonyl, C 1-4 alkyl substituted with Unsubstituted 4 to 7 membered heterocycloalkylcarbonyl, C 1-4 alkylsulfonyl, C 3-6 cycloalkylsulfonyl, or oxetanyl,
- heterocycloalkyl comprises at least one atom selected from N, O and S,
- R 3 is hydrogen, halogen, or C 1-4 alkyl
- R 4 is C 1-6 alkyl or C 3-6 cycloalkyl optionally substituted with one or more halogens;
- R < 5 > is halogen, or C1-4 alkyl optionally substituted with one or more halogens.
- R 1 is hydrogen, halogen, trifluoroC 1-4 alkyl, C 1-4 alkyl, or C 1-4 alkoxy.
- R 4 is trifluoroC 1-4 alkyl, C 1-4 alkyl, or C 3-6 cycloalkyl.
- R 5 is halogen, trifluoroC 1-4 alkyl, or C 1-4 alkyl.
- R 2 is C 1-4 alkyl, C 1-3 alkoxyC 1-4 alkyl, C 3-6 cycloalkylC 1-4 alkyl, C 1-4 alkoxy, C 3-6 cyclo Alkyl, 4- to 7-membered heterocycloalkyl, or C 6-10 aryl substituted with F or Cl, said 4- to 7-membered heterocycloalkyl being optionally substituted with C 1-4 alkyl, trifluoroC 1-4 alkylcarbonyl carbonyl, C 1-4 alkylcarbonyl, C 3-6 cycloalkyl-carbonyl, C 1-4 heterocycloalkyl carbonyl of the substituted or unsubstituted 4 to 7 membered alkyl carbonyl, C 1-4 alkylsulfonyl, C 3-6 cycloalkylsulfonyl, or oxetanyl, wherein said heterocycloalkyl comprises one or more atoms selected from N and <
- R < 2 > may be selected from the following substituents:
- the compound represented by Formula 1 may be selected from the group consisting of the following compounds.
- the inhibitory rate (IC 50 ) of LRRK2 according to the substituent of the compound represented by Formula 1 is as shown in Table 1 below (++++: more than 0 and less than 10 nM, +++: more than 10 nM 100 nM or less, ++: 100 nM or more and 1,000 nM or less, +: 1,000 nM or more and 10,000 nM or less).
- the pharmaceutically acceptable salt of the compound represented by Formula 1 may be an alkali metal salt, an alkaline earth metal salt, an ammonium salt, an amine salt, an acid addition salt, a hydrate salt, .
- inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate and nitrate
- salts of organic acids such as formic acid, tartaric acid, tartaric acid, citric acid, tartaric acid, citric acid, tartaric acid, citric acid, tartaric acid, citric acid, Organic acid salts such as acid salts, gluconic acid salts and fatty acid salts.
- the pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, methanesulfonate, ethanesulfonate, benzenesulfonate and toluenesulfonate Or more.
- the hydrate and solvate of the compound represented by Formula 1 can be prepared by a method well known in the art. Specifically, it is preferably non-toxic and water-soluble, and may be a hydrate and a solvate in which 1 to 5 molecules of water and an alcohol-based solvent (particularly, ethanol, etc.) are combined.
- the prodrug of the compound represented by Formula 1 may be prepared by a method well known in the art, which is a chemical derivative that can be converted into the compound represented by Formula 1 in vivo upon administration .
- the isomer of the compound represented by Formula 1 is not only an optical isomer (for example, enantiomers, diastereomers and mixtures thereof), but also conformation isomers and positional isomers (position isomers).
- R 1 to R 5 are as defined in Formula 1 above.
- the organic solvent may be at least one selected from the group consisting of acetone, 1,4-dioxane, methyl ethyl ketone, N, N-dimethylformamide, N-methylpyrrolidone and ethyl acetate, no.
- step (1) for example, the compound of formula (2) may be reacted with NCS (N-chlorosuccinimide) in a N, N-dimethylformamide solvent at room temperature for 1 to 2 hours.
- NCS N-chlorosuccinimide
- step (2) for example, the compound of formula (4) may be reacted with potassium hydroxide and the compound of formula (5) in a N, N-dimethylformamide solvent at room temperature for 2 hours.
- the compound of formula (2) is reacted with iodine and potassium hydroxide in a N, N-dimethylformamide solvent at 0 ° C to room temperature, followed by addition of iodomethane , Methylfluorosulfonyldifluoroacetate (MFSDA) at 100 to 130 ° C for 4 hours to prepare 2-chloro-7-methyl-5- (trifluoromethyl) -7H-pyrrolo [2,3-d] pyrimidine It is possible.
- MFSDA Methylfluorosulfonyldifluoroacetate
- step (3) for example, the compound of formula (6) and the compound of formula (7) are dissolved in an ethanol solvent, hydrochloric acid is added thereto, and the compound is reacted at 80 ° C for 12 hours.
- R 1 to R 5 are as defined in Formula 1 above.
- the organic solvent may be at least one selected from the group consisting of acetone, dichloromethane, 1,4-dioxane, methyl ethyl ketone, N, N-dimethylformamide, N-methylpyrrolidone and ethyl acetate. But is not limited thereto.
- step (A) for example, the compound of formula (8) can be prepared by reacting the compound of formula (8) with N 2 H 4 and acetonitrile (ACN) at room temperature for 1 to 2 hours.
- ACN acetonitrile
- the compound of formula (10) may be prepared by reacting the compound of formula (9) with 10% KOH at 90 to 110 ° C for 2 to 3 hours.
- step (C) for example, the compound of formula (10) can be prepared by reacting the compound of formula (10) with phosphoryl chloride (POCl 3 ) at 90-110 ° C.
- phosphoryl chloride (POCl 3 ) at 90-110 ° C.
- step (D) for example, the compound of formula (11) may be reacted with the compound of formula (5) in a solvent of N, N-dimethylformamide at 0 ° C to room temperature for 2 hours.
- step (E) for example, the compound of formula (12) can be reacted with mCPBA (m-chloroperoxybenzoic acid) in dichloromethane or N, N-dimethylformamide for 4 hours at room temperature .
- mCPBA m-chloroperoxybenzoic acid
- step (F) for example, the compound of formula (13) may be reacted with p-toluenesulfonic acid and the compound of formula (7) in a N-methylpyrrolidone solvent at 100 to 120 ° C for 6 hours to prepare the compound of formula have.
- the compounds represented by Formula 1 exhibit high LRRK2 inhibitory activity and excellent selectivity for inhibitory activity. Accordingly, the compound represented by Formula 1 and its pharmaceutically acceptable salts, hydrates, solvates, prodrugs and isomers are useful as a preventive or therapeutic agent for degenerative brain diseases requiring inhibition of LRRK2 activity.
- One embodiment provides a pharmaceutical composition for preventing or treating degenerative brain diseases, comprising the compound as an active ingredient.
- the degenerative brain disease may be Parkinson's disease.
- the pharmaceutical composition exhibits selective LRRK2 (Leucine Rich Repeat Kinase2) inhibitory activity.
- the pharmaceutical composition may comprise one or more pharmaceutically acceptable excipients.
- Lubricants such as, for example, magnesium stearate, sodium lauryl sulfate and talc; Excipients such as lactose, sodium citrate, calcium carbonate and dicalcium phosphate; Disintegrants such as starch, alginic acid and certain complex silicates; And various carriers may be used for the preparation of tablets.
- the kind of the carrier may vary depending on the solubility of the active substance, the chemical property, and the administration mode.
- the pharmaceutical composition may be prepared according to a conventional method using one or more pharmaceutically acceptable additives.
- additives may include, among others, diluents, sterile aqueous media and various non-toxic organic solvents, which may additionally contain sweetening, flavoring, coloring or stabilizing agents, if desired.
- the pharmaceutical composition may be formulated into various dosage forms such as tablets, pills, granules, capsules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups according to conventional formulation methods in the pharmaceutical field.
- lactose and high molecular weight polyethylene glycols are advantageous to use.
- they may contain emulsifying agents or agents that facilitate suspension, and diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol or chloroform, or mixtures thereof may be used.
- the pharmaceutical composition may be administered parenterally or orally, if necessary, and may be administered at a dose of 0.5 mg / kg body weight to 5 mg / kg body weight, preferably 1 mg / kg body weight per day for parenteral administration To 4 mg / kg body weight; In the case of oral administration, one or more doses may be administered in an amount of 5 mg / kg body weight to 50 mg / kg body weight, preferably 10 mg / kg body weight to 40 mg / kg body weight.
- the dosage for a patient may vary depending on the weight, age, sex, health condition, diet, administration time, administration method, excretion rate, severity of disease, etc. of each patient.
- a method of treating a degenerative brain disease comprising administering the compound to a patient.
- 2,5-dichloro-7H-pyrrolo [2,3-d] pyrimidine (3.31 g, 17.60 mmol) was added to the N, N-dimethylformamide solvent (33 ml) and cooled to 0 ⁇ ⁇ .
- NaH (1.15 g, 26.40 mmol) was slowly added thereto, and the mixture was stirred at 0 ° C for 30 minutes.
- Iodoethane (1.69 ml, 21.12 mmol) was slowly added dropwise and then the temperature was raised to room temperature and stirred for 2 hours. Water (80 ml) was added to precipitate a solid. After filtration under reduced pressure, 3.15 g (yield: 82%) of the title compound was obtained.
- Step 1 Synthesis of ethyl 4-hydrazinyl-2- (methylthio) pyrimidine-5-carboxylate
- Acetyl nitrate (Acetyl nitrate) was prepared by slowly adding HNO 3 (18 ml) to acetic anhydride (42 ml) at 0 ° C. 1H-pyrazole (10 g) was added to another flask and acetic acid (28 ml) was added. The acetyl nitrate was slowly added to the pyrazole compound at 0 ° C, stirred for 1 hour, and then water was added to precipitate a solid. Filtration under reduced pressure with water gave 16.0 g (yield: 97%) of the desired compound.
- Step 2 Synthesis of tetrahydro-2H-pyran-4-ylmethanesulfonate
- Step 3 Synthesis of 4-nitro-1- (tetrahydro-2H-pyran-4-yl) -3- (trifluoromethyl) -1H-pyrazole
- Step 1 Synthesis of 1-isopropyl-4-nitro-3- (trifluoromethyl) -1H-pyrazole
- Step 1 Synthesis of 4-nitro-1- (oxetan-3-yl) -1H-pyrazole
- tert-Butyl-4-hydroxypiperidine-l-carboxylate (20.0 g, 99.42 mmol) was dissolved in DCM (200 ml). Methanesulfonyl chloride (10 mL, 1.3 eq.) was added thereto, followed by stirring. Triethylamine (41.6 mL, 3.0 eq.) was added and stirred for 1 hour. After the reaction was completed, the mixture was extracted three times with brine and DCM, dried over MgSO 4 and concentrated under reduced pressure to obtain 27.7 g (yield: 99%) of an ivory solid compound.
- Step 1 Synthesis of tert-butyl-3-hydroxyazetidine-1-carboxylate
- Azetidin-3-ol hydrochloride (3.0 g, 27.38 mmol) was dissolved in H 2 O (6 ml).
- K 2 CO 3 (3.78 g, 1.0 eq.) was dissolved in H 2 O (6 mL) and added.
- Di-tert-butyl dicarbonate (5.98 g, 1.0 eq.) was dissolved in THF (27 mL), and the mixture was stirred for 4 hours. After the reaction was completed, ethyl acetate was added thereto, and the mixture was extracted three times, dried and concentrated to obtain 4.7 g (yield: 99%) of yellow target compound.
- tert-Butyl-3-hydroxyazetidine-1-carboxylate (4.7 g, 27.13 mmol) was dissolved in DCM (50 ml). Methanesulfonyl chloride (2.7 ml, 1.3 eq.) was added and stirred. Triethylamine (11.3 mL, 3.0 eq.) was added and stirred for 1 hour. After the reaction was completed, the reaction mixture was extracted three times with brine and DCM, dried over MgSO 4 and concentrated to obtain 6.8 g (yield: 99%) of the desired compound as a brown solid.
- Step 1 Synthesis of tert-butyl-4- (4-nitro-1H-pyrazol-1-yl) piperidine-
- Step 2 Synthesis of tert-butyl-4- (5-chloro-4-nitro-1H-pyrazol-1-yl) piperidine-
- Step 1 Synthesis of l- (4- (5-chloro-4-nitro-lH-pyrazol-l-yl) piperidin-
- Step 1 Synthesis of tert-butyl-4- (4-nitro-1H-pyrazol-1-yl) piperidine-
- Step 1 Synthesis of 4- (4-nitro-1H-pyrazol-1-yl) -1- (oxetan-3- yl) piperidine
- Step 2 Synthesis of 4- (5-chloro-4-nitro-1H-pyrazol-1-yl) -1- (oxetan-
- Step 1 Synthesis of tert-butyl-3- (4-nitro-1H-pyrazol-1-yl) azetidine-
- Step 1 Synthesis of 4-nitro-1- (1- (oxetan-3-yl) azetidin-3-yl) -1H-pyrazole
- Step 1 Synthesis of 4-nitro-1- (tetrahydro-2H-pyran-4-yl) -1H-pyrazole
- Step 1 Synthesis of 1- (4-fluorophenyl) -4-nitro-1H-pyrazole
- Step 1 Synthesis of cyclopropyl (4- (4-nitro-1H-pyrazol-1-yl) piperidin-
- step 2 of Preparation 34 cyclopropyl (4- (4-nitro-1H-pyrazol-1-yl) piperidine was used instead of 4-nitro-3- (trifluoromethyl) -1-yl) methanone (0.28 g, 1.07 mmol) was used in place of 4-chloro-2-fluoroaniline to yield the desired compound (0.10 g, Yield: 34%).
- Preparation 50 Preparation of Intermediate 50 (l- (4- (4-Amino-3-chloro-lH-pyrazol- l-yl) piperidin- l-yl) -2,2,2-trifluoroethane On) >
- Step 1 Synthesis of 1- (1- (methylsulfonyl) azetidin-3-yl) -4-nitro-1H-pyrazole
- step 2 of Preparation 34 21- (1- (methylsulfonyl) azetidin-3-yl) -4-nitro-thiazole was used instead of 4-nitro- 240 mg (yield: 47%) of the desired compound was obtained by the same procedure as in the step 2 of Preparation Example 34, except that 1H-pyrazole (500 mg, 2.03 mmol) was used.
- Step 1 Synthesis of tert-butyl-4- (4-nitro-1H-pyrazol-1-yl) azepane-
- Step 1 Synthesis of tert-butyl 4- (3-chloro-5-methyl-4-nitro-1H-pyrazol-1-yl) piperidine-
- Step 3 Synthesis of (4- (3-chloro-5-methyl-4-nitro-1H-pyrazol-1-yl) piperidin-l-yl) (cyclopropyl) methanone
- Step 1 Synthesis of tert-butyl 4- (3,5-dimethyl-4-nitro-1H-pyrazol-1-yl) piperidine-
- Step 3 of Production Example 25 The procedure of Step 3 of Production Example 25 was repeated to give 0.39 g of the target compound (yield: 99%).
- Step 3 Synthesis of 4- (3,5-dimethyl-4-nitro-1H-pyrazol-1-yl) -1- (methylsulfonyl) piperidine
- the compound was dissolved in 100 mM DMSO at 10 mM and then a solution of LRRK2 activity measurement (50 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) pH 7.5, 10 mM MgCl 2 , 1 mM EGTA (1 ⁇ M to 10 ⁇ M) was serially diluted with 1 ⁇ M -bis (o-aminophenoxy) ethane-N, N, N ', N'-tetraacetic acid, 2 mM DTT (Dithiothreitol) and 0.01% Tween- .
- LRRK2 activity measurement 50 mM HEPES (4- (2-hydroxyethyl) -1-piperazineethanesulfonic acid) pH 7.5, 10 mM MgCl 2 , 1 mM EGTA (1 ⁇ M to 10 ⁇ M
- the compound of the present invention has an inhibitory effect on LRRK2 activity at nM level and has LRRK2 activity inhibitory properties superior to that of LRRK2-IN-1, which was conventionally used.
- LRRK2-IN-1 LRRK2-IN-1
- six tyrosine kinase panel tests were performed on the compounds 25, 28, 30, 31, 32, 33, 35, 42, 43, 46, 47, 51, 52, 55, 57, 58 and 59 As a result, all of them showed high LRRK2 inhibitory activity, confirming excellent selectivity of LRRK2 inhibitory activity.
Abstract
Description
화합물 번호 | IC50 (nM) | 화합물 번호 | IC50 (nM) |
LRRK2-IN-1 | 8.20 | 43 | 5.83 |
25 | 6.67 | 46 | 7.91 |
28 | 6.50 | 47 | 6.48 |
30 | 2.02 | 51 | 4.75 |
31 | 4.66 | 52 | 5.60 |
32 | 2.50 | 55 | 4.49 |
33 | 6.07 | 57 | 7.22 |
35 | 6.66 | 58 | 5.92 |
42 | 5.11 | 59 | 3.94 |
Claims (13)
- 하기 화학식 1로 표시되는 화합물, 및 이의 약학적으로 허용되는 염, 수화물, 용매화물, 전구약물 및 이성질체로 이루어진 군으로부터 선택되는 화합물:[화학식 1]상기 식에서,X는 CH 또는 N이고;R1은 수소, 할로겐, 또는 하나 이상의 할로겐으로 치환되거나 치환되지 않은 C1-4 알킬 또는 C1-4 알콕시이며;R2는 C1-6 알킬, C1-3 알콕시 C1-6 알킬, C3-6 시클로알킬 C1-6 알킬, C1-6 알콕시, C3-6 시클로알킬, 4 내지 7원의 헤테로시클로알킬, 또는 하나 이상의 할로겐으로 치환되거나 치환되지 않은 C6-10 아릴이고;상기 4 내지 7원의 헤테로시클로알킬은 C1-4 알킬, 하나 이상의 할로겐으로 치환되거나 치환되지 않은 C1-4 알킬카보닐, C3-6 시클로알킬카보닐, C1-4 알킬로 치환되거나 치환되지 않은 4 내지 7원의 헤테로시클로알킬카보닐, C1-4 알킬설포닐, C3-6 시클로알킬설포닐, 또는 옥세타닐로 치환될 수 있고,이때, 상기 헤테로시클로알킬은 N, O 및 S 중에서 선택된 하나 이상의 원자를 포함하며,R3은 수소, 할로겐, 또는 C1-4 알킬이며;R4는 하나 이상의 할로겐으로 치환되거나 치환되지 않은 C1-6 알킬 또는 C3-6 시클로알킬;R5는 할로겐, 또는 하나 이상의 할로겐으로 치환되거나 치환되지 않은 C1-4 알킬이다.
- 제1항에 있어서,상기 R1은 수소, 할로겐, 트리플루오로 C1-4 알킬, C1-4 알킬, 또는 C1-4 알콕시인, 화합물.
- 제1항에 있어서,상기 R4는 트리플루오로 C1-4 알킬, C1-4 알킬, 또는 C3-6 시클로알킬인, 화합물.
- 제1항에 있어서,상기 R5는 할로겐, 트리플루오로 C1-4 알킬, 또는 C1-4 알킬인, 화합물.
- 제1항에 있어서,상기 R2는 C1-4 알킬, C1-3 알콕시 C1-4 알킬, C3-6 시클로알킬 C1-4 알킬, C1-4 알콕시, C3-6 시클로알킬, 4 내지 7원의 헤테로시클로알킬, 또는 F 또는 Cl로 치환된 C6-10 아릴이고;상기 4 내지 7원의 헤테로시클로알킬은 C1-4 알킬, 트리플루오로 C1-4 알킬카보닐, C1-4 알킬카보닐, C3-6 시클로알킬카보닐, C1-4 알킬로 치환되거나 치환되지 않은 4 내지 7원의 헤테로시클로알킬카보닐, C1-4 알킬설포닐, C3-6 시클로알킬설포닐, 또는 옥세타닐로 치환될 수 있고,이때, 상기 헤테로시클로알킬은 N 및 O 중에서 선택된 하나 이상의 원자를 포함하는, 화합물.
- 제1항에 있어서,상기 화학식 1로 표시되는 화합물은 하기 화합물들로 이루어진 군으로부터 선택되는, 화합물:1) N-(5-클로로-1-메틸-1H-피라졸-4-일)-7-메틸-5-(트리플루오로메틸)-7H-피롤로[2,3-d]피리미딘-2-아민,2) 5-클로로로-N-(1-이소프로필-3-메톡시-1H-피라졸-4-일)-7-메틸-7H-피롤로[2,3-d]피리미딘-2-아민,3) 5-클로로-N-(3-클로로-1-이소프로필-1H-피라졸-4-일)-7-메틸-7H-피롤로[2,3-d]피리미딘-2-아민,4) 5-클로로-7-메틸-N-(1-(테트라하이드로-2H-피란-4-일)-3-(트리플루오로메틸)-1H-피라졸-4-일)-7H-피롤로[2,3-d]피리미딘-2-아민,5) 5-클로로-N-(5-클로로-1-메틸-1H-피라졸-4-일)-7-메틸-7H-피롤로[2,3-d]피리미딘-2-아민,6) 5-클로로-N-(5-클로로-1-메틸-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,7) 5-클로로-N-(3-클로로-1-이소프로필-1H-피라졸-4-일)-7-이소프로필-7H-피롤로[2,3-d]피리미딘-2-아민,8) 5-클로로-N-(3-클로로-1-이소프로필-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,9) 5-클로로-N-(1-이소프로필-3-(트리플루오로메틸)-1H-피라졸-4-일)-7-메틸-7H-피롤로[2,3-d]피리미딘-2-아민,10) 5-클로로-N-(1-(2-메톡시에틸)-3-(트리플루오로메틸)-1H-피라졸-4-일)-7-메틸-7H-피롤로[2,3-d]피리미딘-2-아민,11) N-(1-부틸-3-(트리플루오로메틸)-1H-피라졸-4-일)-5-클로로-7-메틸-7H-피롤로[2,3-d]피리미딘-2-아민,12) 5-클로로-N-(3-클로로-1-(2-메톡시에틸)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,13) 5-클로로-N-(3-클로로-1-(시클로프로필메틸)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,14) 5-클로로-N-(3-클로로-1-시클로프로필-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,15) 5-클로로-N-(3-클로로-1-시클로프로필-1H-피라졸-4-일)-7-시클로프로필-7H-피롤로[2,3-d]피리미딘-2-아민,16) 5-클로로-N-(5-클로로-1-(옥세탄-3-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,17) 5-클로로-N-(3-클로로-1-(1-메틸피페리딘-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,18) 5-클로로-N-(3-클로로-1-(테트라하이드로-2H-피란-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,19) 5-클로로-N-(3-클로로-1-(2,6-di메틸테트라하이드로-2H-피란-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,20) 5-클로로-N-(3-클로로-1-(1-에틸피페리딘-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,21) 5-클로로-N-(3-클로로-1-(4-플루오로페닐)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,22) 5-클로로-N-(5-클로로-1-(4-클로로페닐)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,23) 1-(4-(5-클로로-4-(5-클로로-7-메틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피페리딘-1-일)에탄온,24) (4-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피페리딘-1-일)(시클로프로필)메탄온,25) 5-클로로-N-(3-클로로-1-(1-(메틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,26) 1-(4-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피페리딘-1-일)-2-메틸프로판-1-온,27) 5-클로로-N-(5-클로로-1-(1-(옥세탄-3-일)피페리딘-4-일)-1H-피라졸-4-일)-7-메틸-7H-피롤로[2,3-d]피리미딘-2-아민,28) 5-클로로-N-(5-클로로-1-(1-(옥세탄-3-일)피페리딘-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,29) 5-클로로-N-(5-클로로-1-(1-(옥세탄-3-일)피페리딘-4-일)-1H-피라졸-4-일)-7-시클로프로필-7H-피롤로[2,3-d]피리미딘-2-아민,30) 5-클로로-N-(3-클로로-1-(1-(메틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-7-시클로프로필-7H-피롤로[2,3-d]피리미딘-2-아민,31) (4-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피페리딘-1-일)(모르폴리노)메탄온,32) (4-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피페리딘-1-일)(4-메틸피페라진-1-일)메탄온,33) 1-(4-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피페리딘-1-일)-2,2-디메틸프로판-1-온,34) 5-클로로-N-(3,5-디메틸-1-(1-(메틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,35) 5-클로로-N-(3-클로로-1-(1-(시클로프로필술포닐)피페리딘-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,36) (R)-5-클로로-N-(3-클로로-1-(1-(메틸술포닐)피롤리딘-3-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,37) (S)-5-클로로-N-(3-클로로-1-(1-(메틸술포닐)피롤리딘-3-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,38) (R)-(3-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피롤리딘-1-일)(시클로펜틸)메탄온,39) (S)-(3-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)피롤리딘-1-일)(시클로펜틸)메탄온,40) 5-클로로-N-(3-클로로-1-(1-(메틸술포닐)azetidin-3-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,41) (3-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)아제티딘-1-일)(시클로프로필)메탄온,42) 5-클로로-N-(3-클로로-1-(1-(메틸술포닐)아제판-4-일)-1H-피라졸-4-일)-7-에틸-7H-피롤로[2,3-d]피리미딘-2-아민,43) (4-(3-클로로-4-(5-클로로-7-에틸-7H-피롤로[2,3-d]피리미딘-2-일아미노)-1H-피라졸-1-일)아제판-1-일)(시클로프로필)메탄온,44) 3-클로로-N-(3-클로로-1-(4-플루오로페닐)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민,45) 3-클로로-N-(5-클로로-1-(1-(옥세탄-3-일)피페리딘-4-일)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민,46) 3-클로로-N-(3-클로로-1-(1-(메틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-1-시클로프로필-1H-피라졸로[3,4-d]피리미딘-6-아민,47) 3-클로로-N-(3-클로로-1-(1-(시클로프로필술포닐)피페리딘-4-일)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민,48) 1-(4-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-1H-피라졸-1-일)피페리딘-1-일)-2,2,2-트리플루오로에탄온,49) 3-클로로-N-(3-클로로-1-(1-(메틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-1-(2,2,2-트리플루오로에틸)-1H-피라졸로[3,4-d]피리미딘-6-아민,50) 3-클로로-N-(5-클로로-1-(1-(옥세탄-3-일)피페리딘-4-일)-1H-피라졸-4-일)-1-(2,2,2-트리플루오로에틸)-1H-피라졸로[3,4-d]피리미딘-6-아민,51) 3-클로로-N-(3-클로로-1-(1-(메틸술포닐)아제판-4-일)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민,52) (4-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-1H-피라졸-1-일)아제판-1-일)(시클로프로필)메탄온,53) 1-(4-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-1H-피라졸-1-일)피페리딘-1-일)-2,2-디메틸프로판-1-온,54) (4-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-1H-피라졸-1-일)피페리딘-1-일)(모르폴리노)메탄온,55) 3-클로로-N-(3-클로로-1-(1-(메틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민,56) (4-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-5-메틸-1H-피라졸-1-일)피페리딘-1-일)(시클로프로필)메탄온,57) (4-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-1H-피라졸-1-일)피페리딘-1-일)(시클로프로필)메탄온,58) 1-(4-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-1H-피라졸-1-일)피페리딘-1-일)에탄온,59) 3-클로로-N-(3-클로로-1-(1-(에틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민,60) (3-(3-클로로-4-(3-클로로-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-일아미노)-1H-피라졸-1-일)아제티딘-1-일)(시클로프로필)메탄온,61) 3-클로로-N-(5-클로로-1-(1-(옥세탄-3-일)아제티딘-3-일)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민,62) 3-클로로-N-(5-클로로-1-(1-(메틸술포닐)피페리딘-4-일)-1H-피라졸-4-일)-1-에틸-1H-피라졸로[3,4-d]피리미딘-6-아민.
- 제1항에 있어서,상기 약학적으로 허용되는 염은 염산염, 브롬화수소산염, 요오드화수소산염, 황산염, 질산염, 메탄술폰산염, 에탄술폰산염, 벤젠술폰산염, 및 톨루엔술폰산염으로 이루어진 군으로부터 선택되는, 화합물.
- 제1항 내지 제8항 중 어느 한 항의 화합물을 유효성분으로 포함하는, 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물.
- 제9항에 있어서,상기 퇴행성 뇌질환이 파킨슨병인, 약학적 조성물.
- 제9항에 있어서,상기 약학적 조성물이 선택적 LRRK2(Leucine Rich Repeat Kinase 2) 억제 활성을 나타내는, 약학적 조성물.
- 퇴행성 뇌질환 예방 또는 치료용 의약(medicament)의 제조를 위한 제1항 내지 제8항 중 어느 한 항의 화합물의 용도.
- 제1항 내지 제8항 중 어느 한 항의 화합물을 환자에게 투여하는 단계를 포함하는, 퇴행성 뇌질환의 치료 방법.
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11202005264PA SG11202005264PA (en) | 2017-12-05 | 2018-12-03 | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
EA202091372A EA202091372A1 (ru) | 2017-12-05 | 2018-12-03 | Производное пирроло(пиразоло)пиримидина в качестве ингибитора lrrk2 |
CA3083583A CA3083583A1 (en) | 2017-12-05 | 2018-12-03 | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
AU2018381574A AU2018381574B2 (en) | 2017-12-05 | 2018-12-03 | Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor |
KR1020207014328A KR20200085779A (ko) | 2017-12-05 | 2018-12-03 | Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 |
MX2020005866A MX2020005866A (es) | 2017-12-05 | 2018-12-03 | Derivado de pirrolo(pirazolo)pirimidina como inhibidor de lrrk2. |
JP2020550569A JP7230053B2 (ja) | 2017-12-05 | 2018-12-03 | Lrrk2阻害剤としてのピロロ(ピラゾロ)ピリミジン誘導体 |
EP18886236.1A EP3722298B1 (en) | 2017-12-05 | 2018-12-03 | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
CN201880078460.2A CN111433208B (zh) | 2017-12-05 | 2018-12-03 | 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物 |
US16/769,667 US11370796B2 (en) | 2017-12-05 | 2018-12-03 | Substituted pyrazoles as LRRK2 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762594773P | 2017-12-05 | 2017-12-05 | |
US62/594,773 | 2017-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019112269A1 true WO2019112269A1 (ko) | 2019-06-13 |
Family
ID=66751116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/015184 WO2019112269A1 (ko) | 2017-12-05 | 2018-12-03 | Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11370796B2 (ko) |
EP (1) | EP3722298B1 (ko) |
JP (1) | JP7230053B2 (ko) |
KR (1) | KR20200085779A (ko) |
CN (1) | CN111433208B (ko) |
AU (1) | AU2018381574B2 (ko) |
CA (1) | CA3083583A1 (ko) |
EA (1) | EA202091372A1 (ko) |
MX (1) | MX2020005866A (ko) |
SG (1) | SG11202005264PA (ko) |
WO (1) | WO2019112269A1 (ko) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021224320A1 (en) | 2020-05-06 | 2021-11-11 | Les Laboratoires Servier | New macrocyclic lrrk2 kinase inhibitors |
CN114163445A (zh) * | 2021-12-06 | 2022-03-11 | 重庆医科大学 | 拉罗替尼中间体及其制备方法 |
US11370796B2 (en) * | 2017-12-05 | 2022-06-28 | Oscotec Inc. | Substituted pyrazoles as LRRK2 inhibitors |
WO2022194976A1 (en) | 2021-03-18 | 2022-09-22 | Les Laboratoires Servier | Macrocyclic lrrk2 kinase inhibitors |
US11780851B2 (en) | 2021-10-27 | 2023-10-10 | H. Lundbeck A/S | LRRK2 inhibitors |
US11958865B1 (en) | 2022-09-15 | 2024-04-16 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (LRRK2) inhibitors |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202110849A (zh) * | 2019-05-27 | 2021-03-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | Dna依賴性蛋白激酶抑制劑 |
CN113880844B (zh) * | 2021-09-29 | 2023-02-14 | 武汉九州钰民医药科技有限公司 | Wee1蛋白激酶抑制剂adavosertib的化学合成方法 |
WO2024054876A1 (en) * | 2022-09-07 | 2024-03-14 | Arvinas Operations, Inc. | Leucine rich repeat kinase 2 (lrrk2) degrading compounds and associated methods of use |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011156698A2 (en) * | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
KR20120102601A (ko) * | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Jak 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
KR20130094693A (ko) * | 2010-04-30 | 2013-08-26 | 셀좀 리미티드 | Jak 저해제로서의 피라졸 화합물 |
KR20140059246A (ko) * | 2011-09-22 | 2014-05-15 | 화이자 인코포레이티드 | 피롤로피리미딘 및 퓨린 유도체 |
KR20150119210A (ko) * | 2013-03-14 | 2015-10-23 | 화이자 인코포레이티드 | 비소세포 폐암의 치료를 위한 egfr t790m 억제제와 egfr 억제제의 조합 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲lrrk2抑制劑的芳基吡咯并吡啶衍生化合物 |
ES2802174T3 (es) | 2014-01-29 | 2021-01-15 | Glaxosmithkline Ip Dev Ltd | Compuestos |
EP3778604A1 (en) * | 2015-02-13 | 2021-02-17 | Dana Farber Cancer Institute, Inc. | Lrrk2 inhibitors and methods of making and using the same |
US11214565B2 (en) * | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
JP2018537502A (ja) * | 2015-12-16 | 2018-12-20 | サウザーン リサーチ インスチチュート | ピロロピリミジン化合物、キナーゼlrrk2阻害剤としての使用、及びその調製方法 |
EP3587422A4 (en) * | 2017-02-22 | 2020-05-06 | Daegu-Gyeongbuk Medical Innovation Foundation | PYRROLO-PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF A PROTEIN KINASE-RELATED DISEASE |
SG11202005264PA (en) * | 2017-12-05 | 2020-07-29 | Oscotec Inc | Pyrrolo(pyrazolo)pyrimidine derivative as lrrk2 inhibitor |
-
2018
- 2018-12-03 SG SG11202005264PA patent/SG11202005264PA/en unknown
- 2018-12-03 AU AU2018381574A patent/AU2018381574B2/en active Active
- 2018-12-03 US US16/769,667 patent/US11370796B2/en active Active
- 2018-12-03 JP JP2020550569A patent/JP7230053B2/ja active Active
- 2018-12-03 MX MX2020005866A patent/MX2020005866A/es unknown
- 2018-12-03 WO PCT/KR2018/015184 patent/WO2019112269A1/ko unknown
- 2018-12-03 KR KR1020207014328A patent/KR20200085779A/ko unknown
- 2018-12-03 CN CN201880078460.2A patent/CN111433208B/zh active Active
- 2018-12-03 CA CA3083583A patent/CA3083583A1/en active Pending
- 2018-12-03 EP EP18886236.1A patent/EP3722298B1/en active Active
- 2018-12-03 EA EA202091372A patent/EA202091372A1/ru unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20120102601A (ko) * | 2009-10-20 | 2012-09-18 | 셀좀 리미티드 | Jak 저해제로서의 헤테로시클릴 피라졸로피리미딘 유사체 |
KR20130094693A (ko) * | 2010-04-30 | 2013-08-26 | 셀좀 리미티드 | Jak 저해제로서의 피라졸 화합물 |
WO2011156698A2 (en) * | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
KR20140059246A (ko) * | 2011-09-22 | 2014-05-15 | 화이자 인코포레이티드 | 피롤로피리미딘 및 퓨린 유도체 |
KR20150119210A (ko) * | 2013-03-14 | 2015-10-23 | 화이자 인코포레이티드 | 비소세포 폐암의 치료를 위한 egfr t790m 억제제와 egfr 억제제의 조합 |
Non-Patent Citations (4)
Title |
---|
HAUSER, MARTIN ET AL., J. ORG, CHEM., vol. 25, 1960, pages 1570 - 1573 |
J. ORG. CHEM., vol. 26, 1961, pages 451 - 455 |
LIU, JING. ET AL., ACS COMB. SCI., vol. 13, 2011, pages 414 - 420 |
See also references of EP3722298A4 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11370796B2 (en) * | 2017-12-05 | 2022-06-28 | Oscotec Inc. | Substituted pyrazoles as LRRK2 inhibitors |
WO2021224320A1 (en) | 2020-05-06 | 2021-11-11 | Les Laboratoires Servier | New macrocyclic lrrk2 kinase inhibitors |
WO2022194976A1 (en) | 2021-03-18 | 2022-09-22 | Les Laboratoires Servier | Macrocyclic lrrk2 kinase inhibitors |
US11780851B2 (en) | 2021-10-27 | 2023-10-10 | H. Lundbeck A/S | LRRK2 inhibitors |
CN114163445A (zh) * | 2021-12-06 | 2022-03-11 | 重庆医科大学 | 拉罗替尼中间体及其制备方法 |
CN114163445B (zh) * | 2021-12-06 | 2023-06-20 | 重庆医科大学 | 拉罗替尼中间体及其制备方法 |
US11958865B1 (en) | 2022-09-15 | 2024-04-16 | H. Lundbeck A/S | Leucine-rich repeat kinase 2 (LRRK2) inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JP7230053B2 (ja) | 2023-02-28 |
CN111433208B (zh) | 2023-06-30 |
EA202091372A1 (ru) | 2020-10-05 |
US11370796B2 (en) | 2022-06-28 |
MX2020005866A (es) | 2020-09-09 |
SG11202005264PA (en) | 2020-07-29 |
KR20200085779A (ko) | 2020-07-15 |
EP3722298A1 (en) | 2020-10-14 |
AU2018381574B2 (en) | 2022-09-15 |
US20210363144A1 (en) | 2021-11-25 |
CA3083583A1 (en) | 2019-06-13 |
AU2018381574A1 (en) | 2020-07-16 |
JP2021505679A (ja) | 2021-02-18 |
EP3722298B1 (en) | 2023-08-02 |
CN111433208A (zh) | 2020-07-17 |
EP3722298A4 (en) | 2021-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019112269A1 (ko) | Lrrk2 억제제로서의 피롤로(피라졸로)피리미딘 유도체 | |
WO2019190259A1 (ko) | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체 | |
WO2017142325A1 (ko) | 단백질 키나아제 저해제인 신규 2,3,5-치환된 싸이오펜 화합물 | |
WO2020171606A1 (ko) | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 | |
WO2018139903A1 (ko) | 피리미딘 화합물 및 그의 의약 용도 | |
WO2017188694A1 (ko) | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 | |
WO2019078522A1 (ko) | 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
EP2760865A2 (en) | Novel heterocyclic derivatives and their uses | |
WO2020235902A1 (ko) | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 | |
WO2018155947A1 (ko) | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 | |
WO2014061970A1 (en) | Sodium channel blockers, preparation method thereof and use thereof | |
WO2020149715A1 (ko) | 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도 | |
AU2019279421A1 (en) | Heterocyclic derivatives and use thereof | |
WO2016032209A2 (ko) | 야누스인산화효소 억제제로서의 치환된 n-(피롤리딘-3-일)-7h-피롤로[2,3-d]피리미딘-4-아민 | |
WO2017034245A1 (ko) | 야누스 키나제 1 선택적 억제제 및 그 의약 용도 | |
WO2021125802A1 (ko) | 신규한 인다졸 유도체 및 이의 용도 | |
EP2331529A2 (en) | Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof | |
WO2016006974A2 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2023017442A1 (en) | Novel plk1 degradation inducing compound | |
WO2018139883A1 (ko) | 다중 표적 키나아제 저해제로서 융합피리미딘 유도체 | |
WO2017164705A1 (ko) | 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물 | |
AU2019344240B2 (en) | Novel thiazole derivatives and pharmaceutically acceptable salts thereof | |
EP3166945A2 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
WO2020263058A1 (ko) | 아미노시아노피리딘 유도체 및 그의 용도 | |
WO2019198940A1 (ko) | 우수한 카이네이즈 저해 활성을 보이는 다양한 치환기를 갖는 피리미딘 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18886236 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 20207014328 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3083583 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2020550569 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018381574 Country of ref document: AU Date of ref document: 20181203 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018886236 Country of ref document: EP Effective date: 20200706 |